Neisseria meningitidis, the cause of epidemic meningitis and acute lethal sepsis, synthesizes surplus lipopolysaccharides (LPSs) during growth, which are released as outer membrane vesicles (OMV) or 'blebs'. Meningococcal disease severity is related to plasma LPS levels. We have compared the biological activities of native outer membrane vesicles (nOMV) to those of purified Nm-LPS (Nm-LPS) and LPS-depleted OMV (dOMV) prepared from N. meningitidis. The LPS content of nOMV was determined spectrophotometrically by quantifying KDO and by silver-stained SDS-PAGE gels. The morphology of the preparations was studied by transmission electron microscopy. The Limulus amoebocyte lysate (LAL) assay was used to quantify LPS in the plasma solutions. The preparations were diluted in endotoxin-free heparin plasma to equal amounts of LPS (w/w) in the range 50-5000 pg/ml. The biological reactivity was tested by: (i) a monocyte target-assay (monocyte purity ≥ 96%); and (ii) a whole blood model, measuring the secretion of TNF-α and IL-6 induction of procoagulant activity in monocytes (PCA). In both models, nOMV induced dose-dependent cell responses (TNF-α, IL-6, PCA) similar to purified Nm-LPS, whereas dOMV induced minimal responses. However, LAL activity was significantly higher for nOMV than for purified Nm-LPS and dOMV. The cellular responses of purified Nm-LPS and nOMV were reduced (>95%) by a specific anti-CD14-antibody.
INTRODUCTION
Meningococcal disease occurs world-wide as endemic infections. Strains of serogroup B and C cause the majority of infections in industrialized countries, whereas strains of serogroup A and to a lesser extent serogroup C cause largescale epidemics in non-industrialised countries. 1 Neisseria meningitidis is an obligate human pathogen which may cause a variety of clinical syndromes ranging from acute lethal septicemia to self-limiting meningococcemia. Most cases are presented as meningitis. In 10-30% of patients, the initial bacteremic phase evolves rapidly to circulatory collapse and multiple organ failure. In meningococcal infections, there is a direct relationship between disease severity and lipopolysaccharide (LPS) concentrations in the circulation. [2] [3] [4] Thus far, this has not been observed in other Gram-negative infections.
During logarithmic growth in vitro, meningococci liberate large amounts of lipopolysaccharide (LPS) as outer membrane vesicles, often referred to as 'blebs'. 5, 6 In addition, meningococci may lyse during growth, leading to release of outer membrane fragments. The existence of native outer membrane vesicles (nOMV) and fragments in vivo has been documented by electron microscopy studies of cerebrospinal fluid and plasma from patients. 3, 7 The formation of outer membrane vesicles has also been reported in other Gram-negative bacteria, and their role in the pathogenicity of disease is increasingly recognized. 8 LPS is assumed to be the major inflammatory inducing principle produced by N. meningitidis. 1, 4 Other cell wall components such as peptidoglycan 9 and secreted enzymes, such as IgA1 proteases, may possibly add to the inflammation. 10 LPSs form complexes with LPS binding protein (LBP) and attach to the CD14-Toll receptor complex on monocytes, macrophages and neutrophil granulocytes which initiates transmembrane signaling and production of inflammatory mediators. [11] [12] [13] [14] The pathogenesis of meningococcal disease has been extensively studied, both clinically, and experimentally. 1, 15, 16 The pathophysiological role of LPS appears to be more firmly established in meningococcal infections than in most other Gram-negative infections. We have performed a series of studies using LPS in its native form, i.e. as an integrated component in outer membrane vesicles (nOMV), and compared the results with those obtained with purified meningococcal LPS (Nm-LPS) and outer membrane vesicles depleted of most of their LPS (dOMV). The latter, deoxycholate-treated preparation is developed for vaccine use, and most of the LPS content has been removed. 17 The remaining 5-10% LPS relative to protein content is tightly bound to outer membrane proteins. 18 The aim of our study was to compare the biological reactivity of equal amounts of meningococcal LPS of the three preparations, i.e. purified Nm-LPS, nOMV and dOMV, in a monocyte-based target cell assay and a whole blood model. The effect was measured as cell activation products, i.e. secretion of tumour necrosis factor (TNF)-α, interleukin (IL)-6 and up-regulation of tissue factor as measured in a clot assay.
MATERIALS AND METHODS

Bacterial strains
N. meningitidis strains 146/85 and 44/76 were isolates obtained from blood cultures from two patients with fulminant septicemia. Strain 44/76 is the production strain for the Norwegian group B OMV-vaccine and is an international reference strain. Strain 146/85 was isolated from a patient with extreme LPS concentrations (patient 1). 2 Both strains belong to the ET-5 clone. 19 The strains have been serologically characterized with monoclonal antibodies in whole-cell ELISA and dot-blotting 20 as B:15:P1,7,16:L3, 7,9. 17 Both strains also produce small amounts of shorter LPS (L8) as determined by SDS-PAGE or ELISA (Brandtzaeg P., unpublished results).
Purified meningococcal LPS (Nm-LPS)
Purified meningococcal LPS (Nm-LPS) was extracted from strain 44/76 and purified as described previously. 3, 21 Briefly, LPS was isolated by three successive extractions: (i) 0.5% (w/v) deoxycholate (DOC) and 10 mM EDTA in 0.1 M Tris/HCl, pH 8.8; (ii) hot phenol extraction; and (iii) phenol-chloroform-hexane, followed by gel filtration chromatography on Sephadex G-75 in the presence of 0.5% (w/v) DOC. LPS was precipitated with 4 volumes of ethanol at -20°C. No protein (<0.3%) was detected in the purified Nm-LPS.
Native outer membrane vesicles (nOMV)
Native outer membrane vesicles (nOMV) were prepared by extraction from strain 146/85 of the bacterial cells as described previously. 22 Briefly, the bacteria were grown overnight on brain heart infusion (BHI) agar plates (37°C, 5% CO 2 ). The colonies were harvested the next day by scraping the bacteria from the plates with a loop. The bacteria were inactivated by heating (60°C, 40 min), and nOMVs were prepared by rapid shaking of the cell pellet with 2 mm glass beads for 40 min in a 0.2 M LiCl/0.1M NaAc buffer pH 5.8, followed by centrifugation (16,000 g, 15 min, 4°C) and then ultracentrifugation twice (125,000 g, 90 min, 4°C). 22, 23 The membrane pellets (nOMVs) were dissolved in distilled water, and the protein concentration determined by a modified Lowry technique (DC-BioRAD, according to the manufacturer's instructions).
Vaccine outer membrane vesicles (dOMV)
Vaccine outer membrane vesicles (dOMV) were prepared by extraction with deoxycholate from N. meningitidis strain 44/76 as previously described. 17 The dOMVs were similar to those used in the Norwegian group B vaccine. The protein content was measured by a modified Lowry technique (DC-BioRAD, according to the manufacturer's instructions).
Peripheral blood mononuclear cells (PBMC)
Peripheral blood mononuclear cells (PBMC) were prepared from blood from two healthy blood donors by density gradient centrifugation and further separation of monocytes by centrifugal elutriation. 24 Cryopreservation and thawing of the cells were done as previously described. 24 The purity of monocytes used in this study was 96% for both donors.
LPS quantification
The LPS content of purified Nm-LPS was quantitated by gas chromatography using 3-hydroxylauric acid (3-OH-12:0) as a marker of neisserial lipid A, as described. 3 In addition, the LPS was analyzed by SDS-PAGE with silverstaining, 18 and with monoclonal anti-LPS antibodies on immunoblots. The LPS content of nOMV was measured by silver-staining SDS-PAGE gels using the purified Nm-LPS preparation as standard, 18 and by KDO analysis. 25 The LPS content of the dOMV was measured by gas chromatography and SDS-PAGE with silver-staining. 3, 18 Liquid-LPS preparations LPS-containing plasma samples were prepared after dilution in human endotoxin-free plasma. 2 From the three different preparations, purified Nm-LPS, nOMV and dOMV, dilutions were made to equal amounts of LPS concentrations in the range of 50-5000 pg/ml in the final assay. For each experiment, an LPS-free control plasma was applied.
Monocyte target assay
Elutriated, purified human monocytes were thawed, 24 resuspended in 5% (v/v) FCS-RPMI 1640 containing 2% (w/v) penicillin/streptomycin, and seeded in microtiterplates (5 x 10 4 monocytes/well, Costar 3595, Corning, NY, USA). The cells were allowed to adhere for 30 min (37°C, 5% CO 2 ) before incubation with a 50 µl LPS -plasma sample, containing either purified Nm-LPS, nOMV or dOMV. The cells were incubated (5 h, 12 h and 24 h, 37°C, 5% CO 2 ), the microtiter plate was centrifuged (47 g, 5 min, 20°C), and the plasma was pipetted off and stored in cryotubes (Nunc, Roskilde, Denmark) at -70°C until analyzed. All experiments were repeated at least three times. Two different donors were used for the doseescalating and longitudinal study.
Blocking of CD14 by monoclonal antibodies
Monocytes (5 x 10 4 /well) were seeded, left for adherence (30 min) and incubated with 25 µl of anti-CD14 antibodies, 20 µg/ml (mAbCD14, murine monoclonal IgG anti-human CD14, ATCC HB-247, The Norwegian Radium Hospital, Oslo, Norway) on ice (15 min). In wells without anti-CD14 antibodies, 25 µl of 5% (v/v) FCS-RPMI 1640 was added to obtain equal well volumes. Subsequently proceedings were as above.
Procoagulant clot assay (PCA)
Procoagulant clot assay (PCA) was performed essentially according to the method of Jungi 26 as modified by Osnes et al. 24, 27 Whole blood model Venous blood was collected without stasis from 5 healthy adult volunteers into LPS-free heparin tubes (Endotubes, Chromogenix, Mølndal, Sweden), pooled into sterile polystyrene tubes (Falcon, Becton Dickinson, NJ, USA), and divided into aliquots of 4 ml in sterile polystyrene tubes. The blood samples were incubated with purified Nm-LPS, nOMV or dOMV in final LPS-concentrations of 0, 250, 1000 and 2500 pg/ml blood. All samples were incubated at 37°C and agitated at 50 rpm. After 0, 5, 12 and 24 h incubation, appropriate tubes were removed, centrifuged (1400 g, 10 min, 4°C), and the plasma was pipetted off into cryotubes (Nunc, Roskilde, Denmark) and stored at -70°C until analyzed. All experiments were repeated at least three times.
Immunoassay
Immunoassays of human TNF-α and IL-6 (Medgenix, BioSource Europe SA, Nivelles, Belgium) were performed according to the instructions in the kits.
Chromogenic Limulus amoebocyte assay LPS in the different plasma-LPS preparations was quantified by the Limulus amoebocyte lysate (LAL) assay, as previously described. 28 Escherichia coli O55B5 LPS (BioWhittaker, Walkersville, USA), 7 endotoxin units (EU)/ng was used as standard.
Electron microscopy
The three preparations of purified Nm-LPS, nOMV, and dOMV were diluted in distilled water. Droplets (5 µl) of the solutions were applied to glow-discharged, carbonfilmed grids for 1 min and negatively stained with 0.5% (w/v) phosphotungstic acid (PTA), pH 7.0, for another minute. The specimens were examined in a transmission electron microscope operated at 100 keV (JEM 1010, Jeol, Tokyo, Japan).
RESULTS
Morphology
The morphology of the three preparations and whole cell preparation of N. meningitidis are shown in Figure  1A -D. As seen from the figure, LPS in native outer membrane vesicles (nOMV; Fig. 1A) shows irregularly shaped vesicles similar in size and shape as the blebbing (arrowheads) and membrane protrusions (arrows) seen in the image of whole bacteria (Fig. 1D) . Some of the nOMVs in Figure 1A are seen to have pits of 3-5 nm in size in the membrane (small arrows). The purified Nm- LPSs appear, mostly, as long smooth membranes (Fig.  1B) , while dOMVs (Fig. 1C) , destined for vaccination, are seen as circular membranes of 60-100 nm.
LPS quantitation by SDS-PAGE and KDO analysis
On silver-stained SDS-gels, the purified Nm-LPS from strain 44/76 showed a major LPS band and a minor, slightly faster moving band (not shown). The major band represents the L3, L7, L9 component and the minor band the L8 component of LPS. 21 The vaccine OMVs and the native OMVs contained qualitatively the same LPS components as the purified Nm-LPS, but the amount of LPS relative to protein was about 7% in dOMVs and 37% and 50% in nOMVs from strains 146/85 and 44/76, respectively (data not shown). In the KDO analysis of nOMV (strain 146/85), the LPS content was 39% relative to protein. This was is in close agreement with 37% LPS relative to protein obtained with the SDS-PAGE analysis (data not shown).
The monocyte target assay
When the cryopreserved monocytes were incubated with increasing amounts of purified Nm-LPS or nOMV, they responded with secretion of TNF-α and IL-6 and up-regulated procoagulant activity in a dose-dependent manner ( Table 1 , Fig. 2A-C) . The same concentrations of LPS in dOMV resulted in minimal or no response ( Table 1 , Fig.  2A-C) . Similar cytokine responses were obtained when stimulating the monocytes with nOMV from strain 44/76 (data not shown).
The TNF-α response was also measured longitudinally at 5, 12 and 24 h. In this model, a LPS concentration of 2500 pg/ml was added. A longitudinal study using dOMV was done and minimal cytokine response was observed at 5,12 and 24 h (data not shown). Thus, dOMV was omitted from further serial experiments. During the longitudinal study, the same pattern of TNFα secretion seen at 12 and 24 h as previously observed at 5 h, i.e. a more pronounced response induced by purified Nm-LPS than nOMV. The maximal response for puri-Cellular activating properties and morphology of meningococcal LPS 441 fied Nm-LPS was seen at 12 h and then gradually declining (Fig. 2D) . The TNF-α response induced by nOMV continued gradually to increase during 24 h of incubation ( Fig. 2D ). Two different monocyte donors were used in the dose escalating and longitudinal studies, respectively, explaining the differences in TNF-α levels ( Table 1 , Fig. 2A,D) .
CD14 mediated monocyte response
To investigate if the cellular responses of nOMV was CD14-mediated, we incubated the monocytes with anti-CD14 blocking antibodies to the monocytes. This resulted in >95% decreased TNF-α responses for both purified Nm-LPS and nOMV (Fig. 3) . Extending the experiment from 5 h to 24 h, the TNF-α response could still be blocked to >95% by adding anti-CD14 antibodies. TNFα levels measured before blocking for 2500 pg/ml Nm-LPS were mean 12,243 (6383-15,247) and mean 6945 (range 6945-11,823) pg/ml and for 2500 pg/ml nOMV mean 3286 (1565-5538) and 4177 (1771-6988) pg/ml at 12 h and 24 h, respectively. Values after anti-CD14 blocking were mean 85 (range 0-180) and mean 98 (range 93-103) pg/ml for Nm-LPS and mean 83 (range 0-154) and mean 163 (range 100-224) pg/ml for nOMV corresponding to >95% blocking while extending LPS stimulation from 5 h to 24 h. Anti-CD14 blocking was tested with two different donors.
The whole blood model
In the whole blood model, the same dose-dependent responses as for the monocyte target assay were observed for purified Nm-LPS and nOMV. Purified Nm-LPS induced higher cytokine responses of TNF-α and IL-6 than nOMV. dOMV induced minimal secretion of TNF-α and IL-6 ( Table 2 , Fig. 4A,B) . A similar cytokine response pattern was obtained by using nOMV from strain 44/76 (data not shown).
In the longitudinal study (5, 12 and 24 h), the TNF-α response for both purified Nm-LPS and nOMV was maximal at 5 h and then gradually declined. Purified 442 Bjerre, Brusletto, Rosenqvist et al. Represent two different monocyte donors after 5 h incubation; a high responder, b low responder; c values from the longitudinal study. All experiments were performed at 37°C; concentration of LPS preparation = 2500 pg/ml. Represents values from 5 different donors, one donor is used in both studies; b represents values from the longitudinal study.
Nm-LPS induced higher levels than nOMV; dOMVs were tested longitudinally as a pilot; no increase in TNFα was seen after 5-24 h and has not been tested further ( Table 2 , Fig. 4C ).
Limulus amoebocyte lysate assay
The Limulus amoebocyte lysate (LAL) assay was used to quantify LPS in the plasma boosted with the different LPS-preparations used in the target assay. LAL-activity was significantly higher for nOMV compared to purified Nm-LPS and dOMV ( Table 3 , Fig. 5 ).
DISCUSSION
The present study shows that native outer membrane vesicles of N. meningitidis induce strong cellular inflammatory responses. Thus, increasing concentrations of nOMV activate responsive blood cells, primarily monocytes, in a dose-dependent manner as purified meningococcal LPS does. Crucial to interpretation of these findings is the use of equal amounts of LPS in the assay. Initially we approached this standardization using the LAL system. Repeatedly, however, we experienced difficulties in standardizing the preparations, possibly due to inhomo-Cellular activating properties and morphology of meningococcal LPS 443 The LAL activity was measured using E. coli O55.B5 (100 pg/ml = 0.7 endotoxin unit [EU]/ml as standard). geneity of the materials. Using KDO determination and SDS-PAGE electrophoresis combined with silver-staining to determine LPS in nOMV, we obtained LPS estimates in close agreement. We thus feel confident that equivalent LPS concentrations have been used in our comparative studies. Anti-CD14 antibodies are known to inhibit activation of LPS responsive cells and reduce toxicity of LPS in chimpanzees. 11, 29 Since most of these experiments have been performed with purified Nm-LPS, we studied the effect of CD14 blockade when human monocytes were stimulated with native outer membrane vesicles (nOMV) as compared with purified Nm-LPS. After CD14 blockade, the cell responses were reduced by more than 95% when stimulated with nOMV. The reduced cell response was in the same order as observed when purified Nm-LPS was used ( Fig.  3) . Thus, CD14 appears to play a crucial role in cell activation by outer membrane vesicles.
The morphology of the nOMV and Nm-LPS preparations differed markedly from the morphology of the dOMV (Fig. 1) . The dark pits observed in the nOMV preparation may reflect porin channels in the membranes assumed to be closely associated with LPS. It is not known whether the shape of these meningococcal structures may influence the binding to CD14-Toll receptor complex. One can speculate whether nOMV and Nm-LPS both exhibiting an irregular shape are more accessible to CD14 after complexing with LBP than the regularly shaped dOMV.
It is interesting that dOMV induced minimal cell activation although the LPS concentration was the same as in purified Nm-LPS and nOMV. Treatment with deoxycholate leaves only LPS molecules which are tightly bound to proteins in the outer membrane. This makes dislocation to the fluid phase difficult and may possibly explain the lack of cell activation. However, the deoxycholate-treated outer membrane vesicles retained the ability to activate the LAL system, although not as strongly as nOMV and Nm-LPS ( Fig. 5 ). This observation suggests that the deoxycholate treatment has not rendered lipid A inactive, i.e. significantly changed the structure and thereby reduced the biological activity.
In our experiments, purified Nm-LPS and nOMV responded in a dose-dependent manner. Purified Nm-LPS appeared to be a more potent activator than native outer membrane vesicles in monocyte activation. Interestingly, the LAL activity induced by native outer membrane vesicles LPS (nOMV) was significantly higher than for purified Nm-LPS and dOMV (Fig. 5 ). One explanation could be that lipid A in its natural position in the outer membrane is able to activate the LPS-sensitive enzyme in the amoebocyte cascade or that LPS molecules are easily translocated to the fluid phase. Purified Nm-LPSs in plasma, on the other hand, form large complexes due to the hydrophobic character of the molecule which somehow restrict the ability to activate LAL.
The pathophysiological effects of nOMV prepared from the 44/76 strain have been studied in a series of experiments simulating meningococcal septicemia with piglets. 30 Infusion elicited a pronounced leukopenia, thrombocytopenia and release of pro-and anti-inflammatory cytokines, i.e. TNF-α, IL-6 and IL-10. The piglets developed a profound hypotension leading to death of several animals receiving the highest dose of nOMV. 30 In a rabbit model, inoculating increasing concentrations of LOS containing outer membrane vesicles from Hemophilus influenzae, a dose-and time-dependent meningeal inflammation was observed. 31 These studies clearly document the biological potency of nOMV in mammals.
What is the relevance of outer membrane vesicles and bacterial cell wall fragments derived from N. meningitidis in human disease? First, the occurrence of these structures has been documented in patients with meningococcal infections. 3, 7 Second, in a few patients with systemic meningococcal disease studied with measurements of LPS and quantitative blood cultures, the LPS levels in plasma by far exceeded the expected level of LPS as judged by the number of live bacteria. 2 Third, ultracentrifugation studies of LPS-containing material in patient plasma suggest that the LAL activity is bound to large LPS-containing structures. 3 These observations together with the findings in this study suggest that outer membrane vesicles play an important role in meningococcal infections.
The dynamic feature of vesicle formation is probably part of the normal growth of Gram-negative bacteria. 8 They are probably formed as evaginations, the outer cell membrane being separated from the peptidoglycan layer during growth and released. 32 The vesicles possess outer membrane proteins (OMPs), LPS, phospholipids and periplasmic constituents such as proteases, phospholipase C, alkaline phosphatases and autolysins. 33 Most experiments aiming to elucidate the biological effects of LPS have been conducted with highly purified Nm-LPS. However, in patients, LPSs are presumably presented to the immune system as part of outer membrane vesicles, fragments of disintegrated bacteria or smaller complexes detached from the outer membrane or periplasma. Therefore, designing experiments in vitro and in vivo should also focus on membrane-bound LPS.
CONCLUSIONS
In conclusion, membrane-bound LPS is biologically active in a dose-dependent manner, and we suggest that nOMV are relevant non-replicating vehicles for delivery of endotoxin thus contributing to the pathophysiology during meningococcal disease.
